文献速递消化与肝胆胰病理细胞病理与分子病理

胰腺FNA样本KRAS突变ddPCR检测的技术与临床实施要点

Droplet digital polymerase chain reaction detection of KRAS mutations in pancreatic FNA samples: Technical and practical aspects for routine clinical implementation.
PubMed 文献 · Cancer Cytopathol · 2024-02-03

该前瞻性研究比较了甲醛固定石蜡包埋细胞学样本与针头冲洗液两种来源用于胰腺导管腺癌KRAS突变ddPCR检测的表现,发现固定过程大幅降低ddPCR灵敏度、增加假阴性风险,而新鲜针头冲洗液灵敏度更高且易于临床实施,无论样本来源如何,细胞学联合KRAS突变检测均改善诊断表现,作者据此提出临床常规整合流程。

要点

  • 固定过程大幅降低ddPCR灵敏度,增加假阴性风险。
  • 新鲜针头冲洗液灵敏度更高,且便于临床实施。
  • 细胞学联合KRAS检测可改善诊断表现。

核心结论

  • 作者建议在临床常规中对EUS-FNA样本采用整合流程进行KRAS分子检测。

研究设计与样本

  • 前瞻性比较研究,对比甲醛固定石蜡包埋细胞学样本与针头冲洗液用于KRAS ddPCR检测的表现。

主要发现

  • 甲醛固定石蜡包埋细胞学样本的分子检测较易建立,但固定过程大幅降低ddPCR灵敏度、增加假阴性风险。
  • 新鲜针头冲洗液样本更适合ddPCR分析,灵敏度更高且易于临床实施。
  • 内镜医师采集液体、运送至实验室及后续冻存不影响DNA数量或质量。
  • 无论样本来源如何,细胞学检查联合KRAS突变检测均改善诊断表现。

临床怎么用

  • 临床开展EUS-FNA样本KRAS ddPCR检测时,优先考虑使用新鲜针头冲洗液而非固定细胞学样本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pancreatic adenocarcinoma (PDAC) is associated with a 5-year survival rate of less than 6%, and current treatments have limited efficacy. The diagnosis of PDAC is mainly based on a cytologic analysis of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) samples. However, the collected specimens may prove noncontributory in a significant number of cases, delaying patient management and treatment. The combination of EUS-FNA sample examination and KRAS mutation detection can improve the sensitivity for diagnosis. In this context, the material used for molecular analysis may condition performance. METHODS: The authors prospectively compared the performance of cytologic analysis combined with a KRAS droplet digital polymerase chain reaction (ddPCR) assay for PDAC diagnosis using either conventional formalin-fixed, paraffin-embedded cytologic samples or needle-rinsing fluids. RESULTS: Molecular testing of formalin-fixed, paraffin-embedded cytologic samples was easier to set up, but the authors observed that the treatment of preanalytic samples, in particular the fixation process, drastically reduced ddPCR sensitivity, increasing the risk of false-negative results. Conversely, the analysis of dedicated, fresh needle-rinsing fluid samples appeared to be ideal for ddPCR analysis; it had greater sensitivity and was easily to implement in clinical use. In particular, fluid collection by the endoscopist, transportation to the laboratory, and subsequent freezing did not affect DNA quantity or quality. Moreover, the addition of KRAS mutation detection to cytologic examination improved diagnosis performance, regardless of the source of the sample. CONCLUSIONS: Considering all of these aspects, the authors propose the use of an integrated flowchart for the KRAS molecular testing of EUS-FNA samples in clinical routine.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Mansour Y, Boubaddi M, Odion T, et al. Droplet digital polymerase chain reaction detection of KRAS mutations in pancreatic FNA samples: Technical and practical aspects for routine clinical implementation. Cancer Cytopathol. 2024. PMID: 38308613. doi:10.1002/cncy.22795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。